Which procedure fits your knee defect?

A focal cartilage defect in the knee — Grade III or IV, full-thickness, typically between 2 and 8 cm² — sits in a range where two quite different surgical strategies are both viable.

AMIC (Autologous Matrix-Induced Chondrogenesis) completes the repair in a single theatre session: the surgeon makes small perforations in the subchondral bone, then covers the site with a collagen membrane that stabilises the blood clot and supports new tissue formation. MACI (Matrix-Induced Autologous Chondrocyte Implantation) follows a different path — a first procedure harvests a small cartilage sample, the cells are expanded in a laboratory over several weeks, and a second operation implants them on a collagen membrane.

Neither approach is designed for diffuse osteoarthritis; both target discrete, focal lesions where the surrounding cartilage remains largely intact.

For defects in the 2–4 cm² range, AMIC is typically a strong primary choice. MACI tends to be favoured when defects exceed roughly 3–5 cm², where the greater tissue yield from laboratory-cultured cells may offer an advantage. In the 3–4 cm² overlap zone, the decision turns on defect geometry, patient circumstances, and whether the logistical and time demands of a two-stage pathway are justified.

Who is a suitable candidate for AMIC?

Suitable patients tend to be between 14 and 60 years of age, with a single, well-defined chondral or osteochondral lesion graded III or IV on the Outerbridge scale. Defect size matters considerably: the procedure is supported by evidence across the 2–8 cm² range. Below 2 cm², standard microfracture alone is generally considered adequate. Above that threshold, the collagen membrane plays a meaningful role — stabilising the blood clot and supporting more durable repair tissue than marrow stimulation can achieve on its own, a pattern borne out in the AMIC Registry (Gille et al., 57 patients, mean defect 3.4 cm²) and confirmed in the 2024 systematic review by Ong et al. across 18 studies and 490 knee patients.

The joint must also be mechanically sound before the procedure is appropriate. The ACL and PCL need to be intact, the menisci must be functioning, and symptoms should have persisted for at least six months despite conservative measures such as physiotherapy, activity modification, or injection-based support.

Several conditions place AMIC out of reach at the focal-repair stage. Generalised osteoarthritis means the damage is too widespread for a single-site repair to be meaningful. Kissing lesions — where cartilage on both opposing joint surfaces is damaged — remove the stable counter-surface the repair depends on. Inflammatory arthropathies such as rheumatoid arthritis, and untreated avascular necrosis, create a biological environment that is incompatible with chondral regeneration.

Limb malalignment is not an automatic bar. Where the mechanical axis is abnormal, a concurrent corrective osteotomy can address the loading problem, after which AMIC remains entirely in scope. Whether a combined approach is appropriate depends on individual anatomy and is determined through consultant assessment.

How AMIC works in a single operation

The procedure unfolds in two sequential steps within a single theatre session, with no laboratory interval between them.

Step one is microfracture: using a small awl, the surgeon creates a series of controlled perforations through the subchondral bone plate at the base of the defect. These channels open into the bone marrow cavity, releasing blood, growth factors, and mesenchymal stem cells — the body's own progenitor cells — directly into the prepared site.

Step two addresses the central weakness of microfracture performed without augmentation. Left uncontained, the blood clot that forms is mechanically unstable and tends to mature into fibrocartilage: a collagen-I dominant tissue that degrades relatively quickly. A porcine Type I/III collagen membrane — Chondro-Gide is the form most widely reported in published series — is trimmed to the exact shape of the defect and secured over it, trapping the clot and providing a three-dimensional scaffold. The scaffold guides stem-cell differentiation toward cartilage-like repair tissue rather than fibrocartilage, which is the biological basis for AMIC's more durable outcomes compared to microfracture alone at defect sizes of 2 cm² and above.

Chondro-Gide is a Class III medical device with more than ten years of positive clinical results across multiple joint types, so the membrane is an established component of the repair pathway rather than an experimental addition. The entire sequence — bone stimulation, scaffold placement, and fixation — is completed arthroscopically or through a mini-open approach in one operation.

How AMIC and MACI differ in practice

The staging gap between these two techniques has been established in earlier sections. What the comparison reveals beyond logistics is a genuine difference in biological strategy, defect-size preference, and the weight of comparative evidence.

Biological mechanism

AMIC recruits the patient's own bone-marrow mesenchymal stem cells in situ — the microfracture channels release them directly into the collagen scaffold at the time of surgery. MACI takes a different route: autologous chondrocytes, harvested at the first procedure, are expanded in laboratory culture and pre-seeded onto the membrane before implantation. The theoretical advantage is a more controlled, chondrocyte-rich graft with tissue characteristics closer to hyaline cartilage. Whether that translates into a clinically meaningful functional advantage over the medium term remains contested in the literature.

Defect size preference

AMIC evidence is strongest in the 2–4 cm² range, with published series extending to 8 cm². MACI's evidence base — anchored by the SUMMIT trial for defects ≥3 cm² and long-term follow-up data confirming durable benefit at ten years — is particularly robust for larger or more complex lesions of 3–5 cm² and above. In the 3–4 cm² overlap zone, both techniques are clinically defensible; individual defect geometry, patient profile, and available resources all bear on which is chosen.

Comparative evidence

The most direct comparative data come from Migliorini et al. (2022, PMC9351375), a systematic review across 46 cited studies, which found AMIC outperformed matrix ACI on key functional scores at approximately 40 months, with lower revision rates. This is a pooled result from heterogeneous cohorts — not a large head-to-head RCT — and should be read with that caveat in mind. The Fossum RCT (41 patients) adds an important counterpoint: Modified Cincinnati scores were comparable between AMIC and ACI-collagen at one and two years, supporting clinical equivalence in the short-to-mid term. Taken together, the evidence positions AMIC as a genuine peer to cell-based repair for focal defects in the 2–4 cm² range, while MACI remains the better-supported choice where defect complexity or size warrants its additional resource burden.

What results patients typically see

Pain reduction is the outcome most patients ask about first. Across 18 studies and 490 patients, the 2024 systematic review by Ong et al. found roughly a 4-point drop on the Visual Analogue Scale — a shift that corresponds to meaningful day-to-day relief, not merely statistical movement in a score. The AMIC Registry cohort reported by Gille et al. (57 patients, mean age 37.3 years, mean defect 3.4 cm²) showed significant improvements in both pain and function at one and two years, with gains maintained at the later follow-up point (p<0.001).

Functional recovery follows a similar trajectory. KOOS, IKDC, and SF-36 scores improved consistently across a multicentre retrospective series of 101 patients with defects averaging 3.44 cm² at approximately 30 months — results drawn from routine surgical practice rather than a tightly controlled trial population, which makes them broadly applicable to the kinds of patients seen in clinic.

On imaging, MRI MOCART scores averaged approximately 75% across published series, indicating substantial defect fill in most cases. These findings span 24–44 months of follow-up, which represents the range in which most of the current AMIC evidence has been reported.

One limitation merits direct acknowledgement: AMIC's evidence base for the knee does not yet extend reliably beyond ten years, whereas MACI has documented follow-up studies at that horizon and beyond. This is a difference in how mature the two bodies of evidence currently are. AMIC data continue to accumulate, but patients and clinicians should factor this gap into longer-term expectations — and a consultant assessment will address how it bears on an individual case.

Recovery and the pathway at MSK Doctors

Recovery from AMIC follows a predictable staged sequence, though individual variation is the norm. For the first four to six weeks the repaired joint is kept non-weight-bearing — the same protected phase required after MACI — to allow the collagen scaffold to stabilise and early repair tissue to establish. Progressive loading begins once consolidation is under way, with most patients returning to low-impact activity around three to six months post-operatively. Full clearance for high-impact sport typically falls between nine and twelve months, reflecting the pace of biological repair rather than the scale of the original defect.

Where pre-existing axis malalignment has been identified during assessment, a corrective osteotomy is planned before or alongside the cartilage procedure — it is part of the pre-operative workup, not an afterthought discovered in theatre.

Understanding what recovery looks like is one part of the decision; confirming candidacy is the other. MSK Doctors consultants at the Sleaford and Grantham centres can evaluate whether AMIC is appropriate without a GP referral and without NHS-style waiting times. A consultation typically covers imaging, clinical history, and — where a detailed functional picture would strengthen the pre-operative plan — AI-assisted markerless motion analysis. Appointments can be booked directly at mskdoctors.com.